Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Open Label, Multi-Center, Study of Maintenance Intravitreous Injections of Macugen (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated With a Modality Resulting in Maculopathy Improvement

NCT00354445 is registered in ClinicalTrials.gov with Eyetech Pharmaceuticals as lead sponsor.

NCT NCT00354445
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00354445 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Open Label, Multi-Center, Study of Maintenance Intravitreous Injections of Macugen (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated With a Modality Resulting in Maculopathy Improvement
Lead sponsor
Eyetech Pharmaceuticals
Phase
Phase 4
Overall status
Unknown status
Start date
June 30, 2006
Completion date
Not reported
Enrollment
1,000
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration (amd)